Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03270878 · ClinicalTrials.gov registry record · Phase 1
Glasdegib Absolute Bioavailability Study
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03270878 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 12 participants.
The verdict
NCT03270878, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study is intended to estimate the absolute bioavailability of Glasdegib by comparison of the pharmacokinetic exposures following administration of an oral, single dose 100 mg tablet vs. an IV infusion of a 50 mg IV dose in the fasted state in a crossover fashion to healthy volunteers.
Interventions
- DRUG Glasdegib Oral Tablet
- DRUG Glasdegib IV infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-09-07 |
| Est. Completion | 2017-10-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03270878
The ClinicalTrials.gov registry entry for NCT03270878 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Glasdegib Oral Tablet is the first listed.
NCT03270878 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03270878 about?
NCT03270878 is a clinical study titled "Glasdegib Absolute Bioavailability Study". This study is intended to estimate the absolute bioavailability of Glasdegib by comparison of the pharmacokinetic exposures following administration of an oral, single dose 100 mg tablet vs. an IV infusion of a 50 mg IV dose in the fasted state in a crossover fashion to healthy volunteers.
What is the current status of trial NCT03270878?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2017-09-07. Estimated completion is 2017-10-30.
What interventions are being tested in trial NCT03270878?
The interventions under investigation include: Glasdegib Oral Tablet (DRUG), Glasdegib IV infusion (DRUG).
Who is sponsoring clinical trial NCT03270878?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.